Journal Club: Week 48 Efficacy of Guselkumab vs. Ustekinumab in Crohn’s Disease: Insights from GALAXI 2 & 3

Thank you to Johnson & Johnson for your support of this Journal Club Video Module.The GALAXI 2 and 3 Phase 3 trials provide critical insights into the 48-week efficacy of guselkumab and ustekinumab in patients with moderate to severely active Crohn’s disease, evaluating outcomes based on prior biologic therapy response. In this Journal Club video module, Alison Moe, PA-C, from Atlanta Gastroenterology, breaks down the trial results, highlighting endoscopic and clinical remission rates, deep remission outcomes, and safety data. Both guselkumab dosing regimens (200 mg and 100 mg subcutaneous maintenance) demonstrated superiority to ustekinumab across key endoscopic response endpoints at week 48, particularly in biologic-naïve and biologic-experienced patients. The study also confirms guselkumab as a viable option for Crohn’s disease patients who have failed previous therapies, offering a targeted IL-23 therapy with consistent clinical benefits in deep remission and long-term disease control.For more details on the GALAXI trials and the latest in IBD treatment advancements, visit the GHAPP website or download the GHAPP ACE app.